<DOC>
	<DOCNO>NCT02811484</DOCNO>
	<brief_summary>The purpose study see effect use one two additional diabetes drug ( dapagliflozin exenatide-LAR ) blood sugar level patient take insulin . This research study do investigate commonly-used medication , medication combination increase insulin dose well .</brief_summary>
	<brief_title>Efficacy Exenatide-LAR Dapagliflozin Overweight/Obese , Insulin Treated Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This single center prospective , randomize , placebo-controlled trial overweight/obese patient insulin treat uncontrolled type 2 diabetes Eligible subject willing participate study randomize one 3 treatment group : Group 1 : Insulin titration + behavioral therapy Basal insulin titration upto 12 week 2 U increment every 3 day ( Fasting glucose goal &lt; 110 ) base self-monitored blood glucose . After 12 week , patient HbA1c &gt; 8 % switch basal bolus regimen . Group 2 : Exenatide-LAR 2mg q week x 24 week + Dapagliflozin placebo x 52 week + titrate basal insulin +behavioral therapy . Group 3 : Exenatide-LAR 2mg q week x 24 week plus Dapagliflozin 5mg QD x 2 week follow 10mg QD x22 week +titrated basal insulin + behavioral therapy . Behavioral therapy deliver registered dietitian include BMIQ program -a web base medical weight loss program .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion Criteria Diagnosis Type 2 diabetes BMI ≥27kg/m^2 Hemoglobin A1C 812 % English speaking provide write consent stable dose metformin and/or glitazone and/or alphaglucosidase inhibitor ≥ 8 week History type 1 diabetes fast cpeptide &lt; .8 ng/ml eGFR &lt; 60 ml/min/1.73 m^2 urine albumintocreatinine ratio great equal 300 mg/g AST/ALT great equal 2.5 upper limit normal history infectious liver disease ( HBV , HCV ) creatine kinase great equal 3 time upper limit normal unstable serious cardiovascular , renal , hepatic disease symptom severely uncontrolled diabetes history 1 episode severe/major hypoglycemia within 6 month , active/history bladder cancer female patient pregnant intend become pregnant woman breastfeed personal/family history medullary thyroid cancer MEN2 fast triglyceride level &gt; 500 mg/dl history confirm pancreatitis know hypersensitivity allergy exenatide dapagliflozin currently enrol discontinue within last 30 day another study condition precludes patient follow complete protocol history diabetic ketoacidosis antidiabetes medication list inclusion criterion within 8 week screen history previous bariatric surgery plan bariatric surgery course study clinically significant abnormal free T4/TSH require initiation adjustment thyroid treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Obesity</keyword>
</DOC>